tetano
Editor, Senior Moderator
J Med Virol
. 2024 Mar;96(3):e29528.
doi: 10.1002/jmv.29528. A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant
Liuhai Zheng[SUP] 1 2 [/SUP], Huifang Wang[SUP] 1 [/SUP], Xueyan Liu[SUP] 1 [/SUP], Chengchao Xu[SUP] 1 3 4 [/SUP], Mingxiong Tian[SUP] 5 [/SUP], Guangwei Shi[SUP] 2 [/SUP], Chongzhi Bai[SUP] 6 [/SUP], Zhijie Li[SUP] 1 [/SUP], Jigang Wang[SUP] 1 2 4 7 8 [/SUP], Shuwen Liu[SUP] 2 [/SUP]
Affiliations
The emerging Omicron subvariants have a remarkable ability to spread and escape nearly all current monoclonal antibody (mAb) treatments. Although the virulence of SARS-CoV-2 has now diminished, it remains a significant threat to public health due to its high transmissibility and susceptibility to mutation. Therefore, it is urgent to develop broad-acting and potent therapeutics targeting current and emerging Omicron variants. Here, we identified a panel of Omicron BA.1 spike receptor-binding domain (RBD)-targeted nanobodies (Nbs) from a naive alpaca VHH library. This panel of Nbs exhibited high binding affinity to the spike RBD of wild-type, Alpha B.1.1.7, Beta B.1.351, Delta plus, Omicron BA.1, and BA.2. Through multivalent Nb construction, we obtained a subpanel of ultrapotent neutralizing Nbs against Omicron BA.1, BA.2, BF.7 and even emerging XBB.1.5, and XBB.1.16 pseudoviruses. Protein structure prediction and docking analysis showed that Nb trimer 2F2E5 targets two independent RBD epitopes, thus minimizing viral escape. Taken together, we obtained a panel of broad and ultrapotent neutralizing Nbs against Omicron BA.1, Omicron BA.2, BF.7, XBB.1.5, and XBB.1.16. These multivalent Nbs hold great promise for the treatment against SARS-CoV-2 infection and could possess a superwide neutralizing breadth against novel omicron mutants or recombinants.
Keywords: Omicron; SARS-CoV-2; multivalent; neutralizing Nbs; receptor-binding domain.
. 2024 Mar;96(3):e29528.
doi: 10.1002/jmv.29528. A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant
Liuhai Zheng[SUP] 1 2 [/SUP], Huifang Wang[SUP] 1 [/SUP], Xueyan Liu[SUP] 1 [/SUP], Chengchao Xu[SUP] 1 3 4 [/SUP], Mingxiong Tian[SUP] 5 [/SUP], Guangwei Shi[SUP] 2 [/SUP], Chongzhi Bai[SUP] 6 [/SUP], Zhijie Li[SUP] 1 [/SUP], Jigang Wang[SUP] 1 2 4 7 8 [/SUP], Shuwen Liu[SUP] 2 [/SUP]
Affiliations
- PMID: 38501378
- DOI: 10.1002/jmv.29528
The emerging Omicron subvariants have a remarkable ability to spread and escape nearly all current monoclonal antibody (mAb) treatments. Although the virulence of SARS-CoV-2 has now diminished, it remains a significant threat to public health due to its high transmissibility and susceptibility to mutation. Therefore, it is urgent to develop broad-acting and potent therapeutics targeting current and emerging Omicron variants. Here, we identified a panel of Omicron BA.1 spike receptor-binding domain (RBD)-targeted nanobodies (Nbs) from a naive alpaca VHH library. This panel of Nbs exhibited high binding affinity to the spike RBD of wild-type, Alpha B.1.1.7, Beta B.1.351, Delta plus, Omicron BA.1, and BA.2. Through multivalent Nb construction, we obtained a subpanel of ultrapotent neutralizing Nbs against Omicron BA.1, BA.2, BF.7 and even emerging XBB.1.5, and XBB.1.16 pseudoviruses. Protein structure prediction and docking analysis showed that Nb trimer 2F2E5 targets two independent RBD epitopes, thus minimizing viral escape. Taken together, we obtained a panel of broad and ultrapotent neutralizing Nbs against Omicron BA.1, Omicron BA.2, BF.7, XBB.1.5, and XBB.1.16. These multivalent Nbs hold great promise for the treatment against SARS-CoV-2 infection and could possess a superwide neutralizing breadth against novel omicron mutants or recombinants.
Keywords: Omicron; SARS-CoV-2; multivalent; neutralizing Nbs; receptor-binding domain.